%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2015-12-22T13:44:39+01:00
2015-12-22T13:44:39+01:00
Adobe InDesign CS6 (Macintosh)
2015-12-22T13:44:38+01:00
uuid:94e129b6-6e4d-7d4f-a26f-64bcd82f8236
xmp.did:02C377090B2068118083FA3CB7EBA2D6
xmp.id:4EB27B48232068118C14B36018BD080B
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2015-12-22T13:44:38+01:00
xmp.iid:0A801174072068118C14A8A68CAEBE5F
xmp.did:02C377090B2068118083FA3CB7EBA2D6
xmp.did:02C377090B2068118083FA3CB7EBA2D6
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
36 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
10 0 0 10 35.761 697.6063 Tm
(306)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
0 1 0 0 k
/GS0 gs
/C2_0 1 Tf
10 0 0 10 56.6929 645.6459 Tm
<0051>Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.378 Tw /Span<>> BDC
( )Tj
EMC
(R)Tj
/Span<>> BDC
(E)Tj
EMC
(F)Tj
/Span<>> BDC
(E)Tj
EMC
(R)Tj
/Span<>> BDC
(EN)Tj
EMC
(C)Tj
/Span<>> BDC
(ES)Tj
EMC
/T1_2 1 Tf
0.019 Tw 9 0 0 9 56.6929 626.1459 Tm
[([1] Cherry D.K., W)92(oodwell D.A., Rechtsteiner E.A. Na)]TJ
0 Tw (-)Tj
0.033 Tw 0 -1.167 TD
[(tional )37.3(Ambulatory Medical Car)18(e Survey: 2005 summa)]TJ
0 Tw (-)Tj
0 -1.167 TD
[(ry)111(. )]TJ
/T1_3 1 Tf
[(Adv)55(. Data.)]TJ
/T1_2 1 Tf
( 29, 387, 1-39, 2007.)Tj
0.069 Tw 0 -1.167 TD
[([2] Oskarsson J.P)129(., Halldorsson S. )36.7(An evaluation of di)]TJ
0 Tw (-)Tj
0.03 Tw T*
[(agnosis and tr)18(eatment of acute sinusitis at thr)18(ee health )]TJ
0 Tw 0 -1.167 TD
[(car)18(e centers. )]TJ
/T1_3 1 Tf
(Laeknabladid.)Tj
/T1_2 1 Tf
( 96, 531-535, 2010.)Tj
-0.04 Tw 0 -1.167 TD
[([3] )0.6(W)92(ang )0.5(D.Y)111(., )0.5(W)92(ar)18(dani )0.6(R.S., )0.6(Singh )0.5(K., )0.6(et )0.5(al. )37.6(A)55( )0.5(survey )0.6(on )]TJ
0.121 Tw T*
[(the management of acute r)18(hinosinusitis among )37.1(Asian )]TJ
0 Tw 0 -1.167 TD
(physicians. )Tj
/T1_3 1 Tf
[(Rhinology)37(.)]TJ
/T1_2 1 Tf
[( 49, 264-271, 201)55(1.)]TJ
0.1 Tw 0 -1.167 TD
[([4] Hof)18(fmans R., Schermer T)74(., van der Linde K., et al. )]TJ
-0.029 Tw T*
[(Rhinosinusitis in morbidity r)18(egistrations in Dutch Gen)]TJ
0 Tw (-)Tj
0.184 Tw 0 -1.167 TD
[(eral Practice: a r)18.1(etr)18(ospective case-contr)18.1(ol study )]TJ
/T1_3 1 Tf
0 Tw (BMC )Tj
0 -1.167 TD
(Fam, Pract. )Tj
/T1_2 1 Tf
[(1)54.9(1, 16, 120-128, 2015. )]TJ
0.102 Tw T*
[([5] Fokkens W)92(.J., Lund V)129(.J., Mullol J., et al. The Eur)18.1(o)]TJ
0 Tw (-)Tj
-0.038 Tw 0 -1.167 TD
[(pean position paper on r)18(hinosinusitis and nasal polyps. )]TJ
/T1_3 1 Tf
0 Tw 0 -1.167 TD
[(Rhinology)37(.)]TJ
/T1_2 1 Tf
( \(Suppl. 23\), 1-299, 2012.)Tj
0.061 Tw T*
([6] Lau J., Zucker D., Engels E.A., et al. Diagnosis and )Tj
0.206 Tw 0 -1.167 TD
[(tr)18(eatment of acute bacterial r)18(hinosinusitis. )]TJ
/T1_3 1 Tf
(Evid. Rep. )Tj
0 Tw 0 -1.167 TD
[(T)111(echnol. Assess. )]TJ
/T1_2 1 Tf
(9, 1-5, 1999.)Tj
0.066 Tw T*
[([7] )37.3(Ahovuo-Saloranta )37.4(A., Borisenko O.V)129.1(., Kovanen N., )]TJ
0.042 Tw 0 -1.167 TD
[(et )0.6(al. )37.5(Antibiotics )0.6(for )0.6(acute )0.5(maxillary )0.6(sinusitis. )]TJ
/T1_3 1 Tf
0 Tw 20.456 0 Td
(Cochrane )Tj
-20.456 -1.167 Td
[(Database Syst. Rev)55.1(.)]TJ
/T1_2 1 Tf
( CD000243, 2008.)Tj
-0.005 Tc 0.158 Tw 0 -1.167 TD
[([8] )0.5(Stuck )0.6(B.A., )0.5(Bachert )0.5(C., )0.5(Federspil )0.5(P)129(., )0.5(et )0.6(al. )0.5(German)-5( )]TJ
0.19 Tw 0 -1.167 TD
[(Society of Otor)18(hinolaryngology)111(, Head and Neck Sur)]TJ
0 Tc 0 Tw 23.919 0 Td
(-)Tj
-0.005 Tc 0.097 Tw -23.919 -1.167 Td
[(gery)111(. Rhinosinusitis guidelines-unabridged version: S2)-5( )]TJ
0.089 Tw 0 -1.167 TD
[(guidelines fr)17.9(om the German Society of Otor)17.9(hinolaryn)]TJ
0 Tc 0 Tw (-)Tj
-0.005 Tc -0.049 Tw 0 -1.167 TD
[(gology)111(, Head and Neck Sur)18(gery)111(. )]TJ
/T1_3 1 Tf
0.005 Tw (HNO.)Tj
/T1_2 1 Tf
-0.049 Tw ( 60, 141-162, 2012.)Tj
0 Tc -0.042 Tw 0 -1.167 TD
[([9] Rosenfeld R.M., Piccirillo J.F)92(., Chandrasekhar S.S., et )]TJ
0.047 Tw T*
[(al. Clinical practice guideline \(update\): )36.6(Adult Sinusitis )]TJ
0.108 Tw 0 -1.167 TD
[(Executive Summary)111(. )]TJ
/T1_3 1 Tf
[(Otolaryngol. Head Neck Sur)18(g)]TJ
/T1_2 1 Tf
(. 152, )Tj
0 Tw 0 -1.167 TD
(598-609, 2015.)Tj
0.224 Tw T*
[([10] Falagas M.E., Karageor)18.1(gopoulos D.E., Gramma)]TJ
0 Tw (-)Tj
0.119 Tw 0 -1.167 TD
[(tikos )37.3(A.P)129(., Matthaiou D.K. Ef)18(fectiveness and safety of )]TJ
0.102 Tw 0 -1.167 TD
(short vs. long duration of antibiotic therapy for acute )Tj
-0.046 Tw T*
(bacterial sinusitis: a meta-analysis of randomized trials. )Tj
/T1_3 1 Tf
0 Tw 0 -1.167 TD
[(Br)74(. J. Clin. Pharmacol.)]TJ
/T1_2 1 Tf
( 67, 161-171, 2009.)Tj
0.293 Tw 0 -1.167 TD
[([1)55(1] Ber)18.1(gogne-Ber)18(ezin E. Contr)18.1(olling acute bacterial )]TJ
0.231 Tw T*
[(maxillary )0.6(sinusitis. )]TJ
/T1_3 1 Tf
9.09 0 Td
[(Expert )0.6(Opin )0.6(Pharmacother)74(.)]TJ
/T1_2 1 Tf
[( )0.6(3,1471-)]TJ
0 Tw -9.09 -1.167 Td
(1479, 2002.)Tj
0.105 Tw T*
[([12] )37.1(Antimicr)18.1(obial tr)18(eatment guidelines for acute bac)]TJ
0 Tw (-)Tj
0.029 Tw T*
[(terial )0.5(r)18(hinosinusitis. )0.6(Sinus )0.5(and )37.4(Aller)18.1(gy Health )0.5(Partner)]TJ
0 Tw 23.919 0 Td
(-)Tj
-23.919 -1.167 Td
(ship. )Tj
/T1_3 1 Tf
[(Otolaryngol. Head Neck Sur)18.1(g.)]TJ
/T1_2 1 Tf
( 123, 5-31, 2000.)Tj
0.089 Tw T*
[([13] )37.3(Anon J.B., Jacobs M.R., Poole M.D., et al. )37.3(Antimi)]TJ
0 Tw (-)Tj
0.125 Tw 26.142 51.301 Td
[(cr)18(obial tr)18(eatment guidelines for acute bacterial r)18(hino)]TJ
0 Tw (-)Tj
T*
(sinusitis. )Tj
/T1_3 1 Tf
(Otolaryngol. Head Neck)Tj
/T1_2 1 Tf
( )Tj
/T1_3 1 Tf
[(Sur)18(g.)]TJ
/T1_2 1 Tf
( 130, 1-45, 2004.)Tj
0.099 Tw 0 -1.167 TD
[([14] )37.4(Anon J.B. Curr)18(ent )0.5(management of acute bacterial )]TJ
0.072 Tw 0 -1.167 TD
[(r)18(hinosinusitis and the r)18(ole of moxifloxacin )]TJ
/T1_3 1 Tf
(Clin. Infect. )Tj
0 Tw T*
(Dis.)Tj
/T1_2 1 Tf
( 41, S167-S176, 2005.)Tj
0.048 Tw 0 -1.167 TD
[([15] Falser N., Mittermayer H., W)92(euta H. )37.1(Antibacterial )]TJ
0.044 Tw 0 -1.167 TD
[(tr)18(eatment )0.6(of )0.5(otitis )0.6(and )0.6(sinusitis )0.6(with )0.5(cipr)18(ofloxacin )0.7(and )]TJ
0 Tw T*
(penicillin V - a comparison )Tj
/T1_3 1 Tf
(Infection. )Tj
/T1_2 1 Tf
(16, S51-S54, 1988.)Tj
0.303 Tw 0 -1.167 TD
[([16] Gehanno P)129(., Ber)18(che P)129(. and the Sinusitis Study )]TJ
0.264 Tw 0 -1.167 TD
[(Gr)18(oup. Sparfloxacin versus cefur)18.1(oxime axetil in the )]TJ
-0.019 Tw T*
[(tr)18(eatment )0.6(of )0.5(acute )0.5(pur)8(ulent )0.6(sinusitis. )]TJ
/T1_3 1 Tf
16.439 0 Td
[(J. )0.5(Antimicr)18.1(ob. )0.5(Che)]TJ
0 Tw (-)Tj
-16.439 -1.167 Td
[(mother)74(. )]TJ
/T1_2 1 Tf
[(37, 105-1)55(14, 1996.)]TJ
0.059 Tw T*
([17] Hadley J.A., Mosges R., Desosiers M., Haverstock )Tj
0.025 Tw T*
[(D., van V)111(eenhuyzen D., Herman-Gnjidic Z. Moxifloxa)]TJ
0 Tw (-)Tj
0.11 Tw 0 -1.167 TD
(cin five-day therapy versus placebo in acute bacterial )Tj
0 Tw 0 -1.167 TD
[(r)18(hinosinusitis )]TJ
/T1_3 1 Tf
(Laryngoscope.)Tj
/T1_2 1 Tf
( 120, 1057-1062, 2010.)Tj
0.149 Tw T*
[([18] Reato G., Cuf)18(fini )36.9(A.M., T)90(ullio V)129(., et al. Immuno)]TJ
0 Tw (-)Tj
0.11 Tw 0 -1.167 TD
[(modulating ef)18(fect of antimicr)18(obial agents on cytokine )]TJ
-0.032 Tw 0 -1.167 TD
[(pr)18(oduction by human polymorphonuclear neutr)18.1(ophils. )]TJ
/T1_3 1 Tf
0 Tw T*
[(Int. J. Antimicr)18.1(ob. Agents.)]TJ
/T1_2 1 Tf
( 23, 150-154, 2004.)Tj
0.052 Tw 0 -1.167 TD
([19] Passali D. Penetrazione nella mucosa rinosinusale )Tj
0.116 Tw 0 -1.167 TD
[(ed )0.5(ef)18(ficacia di )0.5(pr)8(ulifloxacina )0.5(nella )0.5(rinosinusite. )]TJ
/T1_3 1 Tf
0 Tw 21.585 0 Td
(Nuove )Tj
0.149 Tw -21.585 -1.167 Td
[(Pr)18(ospettive in T)111(erapia)]TJ
/T1_2 1 Tf
[( 2, \(Suppl. 1\), 1-8, 2010. Pr)18(oceed)]TJ
0 Tw (-)Tj
0.025 Tw 0 -1.167 TD
[(ings XXXVIII Societas ORL)37( Latina Lecce settembr)18.1(e 1-4, )]TJ
0 Tw 0 -1.167 TD
(Mediprint 2010.)Tj
0.072 Tw T*
[([20] )0.5(Concia )0.6(E., )37.5(Allegranzi )0.6(B., )0.6(Ciottoli )0.6(G.B., )0.5(et )0.6(al. )0.5(Pene)]TJ
0 Tw (-)Tj
-0.016 Tw 0 -1.167 TD
[(tration of orally administer)18.1(ed pr)8(ulifloxacin into human )]TJ
0 Tw 0 -1.167 TD
(lung tissue. )Tj
/T1_3 1 Tf
(Clin. Pharmacokinet.)Tj
/T1_2 1 Tf
( 44, 1287-1294, 2005.)Tj
0.171 Tw T*
[([21] De )0.5(Benedetto )0.5(M., Passali )0.5(D., T)92(omacelli )0.5(G., et )0.5(al. )]TJ
0.151 Tw 0 -1.167 TD
[(Penetration of pr)8(ulifloxacin into sinus mucosa of pa)]TJ
0 Tw (-)Tj
0.091 Tw 0 -1.167 TD
[(tients )0.6(under)18(going )0.5(paranasal )0.6(sinus )0.5(elective )0.7(endoscopic )]TJ
0 Tw T*
[(sur)18(gery )]TJ
/T1_3 1 Tf
[(J. Chemother)74.1(.)]TJ
/T1_2 1 Tf
( 24, 26-31, 2012.)Tj
0.008 Tw 0 -1.167 TD
[([22] Mehrzad R., Barza M. W)92(eighing the adverse car)18.1(di)]TJ
0 Tw (-)Tj
-0.01 Tw 0 -1.167 TD
[(ac ef)18(fects of fluor)18(oquinolones: )0.5(a risk perspective )]TJ
/T1_3 1 Tf
(J. Clin. )Tj
0 Tw T*
(Pharmacol.)Tj
/T1_2 1 Tf
[( 55, 1)55(198-1206, 2015.)]TJ
0.017 Tw 0 -1.167 TD
[([23] Bassetti M., Carnelutti )37.2(A. Infezioni delle vie urina)]TJ
0 Tw (-)Tj
0.185 Tw 0 -1.167 TD
[(rie: )0.6(appr)18(opriatezza )0.6(in )0.5(antibioticoterapia.)]TJ
/T1_3 1 Tf
[( )0.5(Ur)18(ologia.)]TJ
/T1_2 1 Tf
[( )0.5(81, )]TJ
0 Tw T*
(26-30, 2014.)Tj
0.021 Tw 0 -1.167 TD
[([24] Fosch S., Fogolin N., )37.3(Azzar)18(oni E., et al. V)92(ulvovagi)]TJ
0 Tw (-)Tj
0.379 Tw 0 -1.167 TD
[(nitis: corr)18(elation with pr)18.1(edisposing factors, clinical )]TJ
-0.011 Tw T*
[(manifestations )0.7(and )0.5(micr)18(obiological )0.7(studies. )]TJ
/T1_3 1 Tf
19.392 0 Td
[(Rev)55(. )0.5(Ar)18(gent )]TJ
0 Tw -19.392 -1.167 Td
[(Micr)18(obiol.)]TJ
/T1_2 1 Tf
( 38, 202-205, 2006.)Tj
0.041 Tw T*
[([25] T)92(empera G., Furneri P)129(.M., Cianci )37.2(A., et al. The im)]TJ
0 Tw (-)Tj
0.008 Tw T*
[(pact )0.5(of pr)8(ulifloxacin )0.6(on vaginal )0.5(Lactobacillus )0.5(micr)18.1(oflo)]TJ
0 Tw (-)Tj
0 -1.167 TD
(ra: an )Tj
/T1_3 1 Tf
(in vivo)Tj
/T1_2 1 Tf
[( study)111.1(. )]TJ
/T1_3 1 Tf
[(J. Chemother)74(.)]TJ
/T1_2 1 Tf
( 21, 646-650, 2009.)Tj
ET
endstream
endobj
28 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 56.9429 708.6614 cm
0 0 m
0 -28.346 l
S
Q
q 1 0 0 1 -14.1732 694.2382 cm
0 0 m
581.102 0 l
S
Q
endstream
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 9 0 0 9 62.3622 697.6063 Tm
(D. Passali, et al.)Tj
ET
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
39 0 obj
<>stream
H\j >wIٲK} Thswe7#oڧhͲC62N"8jveݶxZ3̬PpnE=s
6#쾚n[ TEW1!h;oe|n<5#g0#*UCLfhԿx~UEH2&qJ|